IOVA ALERT: Lawsuit Filed for Securities Fraud Against Iovance by Levi & Korsinsky

A securities fraud class action lawsuit has been filed against Iovance Biotherapeutics, Inc. The deadline for interested parties to participate in this legal action is July 14, 2025. The lawsuit has been initiated by Levi & Korsinsky, a law firm based in New York City.

The class action lawsuit alleges that Iovance Biotherapeutics, Inc. engaged in deceptive practices that misled and harmed investors. The allegations in the lawsuit center around violations of federal securities laws.

Investors who purchased shares of Iovance Biotherapeutics, Inc. between a specified period are eligible to participate in this class action lawsuit. The lawsuit aims to recover damages on behalf of investors who suffered financial losses due to the alleged securities fraud committed by the company.

Securities fraud involves misleading or false information provided by a company that leads to financial losses for investors. In this case, the lawsuit against Iovance Biotherapeutics, Inc. alleges that the company misrepresented or failed to disclose material information that would have impacted investors’ decisions to buy or sell stock in the company.

The deadline to join the class action lawsuit against Iovance Biotherapeutics, Inc. is July 14, 2025. Investors who believe they may have been affected by the alleged securities fraud perpetrated by the company during the specified period are encouraged to seek legal counsel and participate in the lawsuit to potentially recover their losses.

It is essential for investors to understand their rights and options when they suspect securities fraud has occurred. Class action lawsuits provide a means for investors to seek recourse for financial losses incurred due to deceptive practices by companies.

Levi & Korsinsky, the law firm representing investors in this class action lawsuit, has a track record of pursuing justice on behalf of individuals and groups harmed by securities fraud. Their expertise in litigating such cases gives investors confidence that their interests will be vigorously defended.

If you believe you may have been affected by the alleged securities fraud by Iovance Biotherapeutics, Inc., it is crucial to act promptly and seek legal advice. The deadline to join the class action lawsuit is approaching, and participation in the legal action may be the best course of action to recover financial losses incurred as a result of the company’s deceptive practices.